{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 90,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "roadmap",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard oncology clinical trial design (dose escalation followed by expansion).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/46",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.67,
        "x": 0.24,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Two-part trial design flow from Dose Escalation to Dose Expansion",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a662afc-6c91-4e43-9221-c7cb894bb6cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours (who have failed on, refused or are ineligible for the standard of care (SoC))",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b8add73-fc54-4e2f-a420-def520e47edc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "*Solid tumours under consideration include ovarian cancer, pancreatic cancer, HR+ HER2- breast cancer, head & neck cancer, NSCLC and colorectal cancer – SoC will vary for each disease cohort",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2093239-4e72-4a7b-b5fa-2be52344c10d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c51da23-2a44-4df9-8f90-53cd5153c801",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c997006f-1c00-48bc-9d65-935ec333aabd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad855db8-b5ee-4a7c-aa3d-57de43a2e601",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "d63aac91-e13a-4c4e-8099-c5fc62572471",
      "evidence": "Standard oncology trial structure (Dose Escalation -> RP2D -> Dose Expansion)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 90,
      "from": 21,
      "beatId": "08c298bd-8dc4-4aa8-832d-c7b35097d152",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The presentation deck ends with a call to action, encouraging investors to take action",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}